Evidence map›Paper›PMID 41402633›Full record

ArticleOncogene2026

YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis.

Jizhuang Luo, Xin Xu, Yaohui Chen, Yiwen Huang, Yiman Huang, Yajuan Zhang, Lifang Ma, Tianxiang Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jizhuang Luo *Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xin Xu *Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yaohui Chen *Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yiwen HuangShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yiman HuangShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yajuan ZhangShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhangyajuan2013@sibcb.ac.cn.ORCID http://orcid.org/0009-0009-5002-2535
Lifang MaDepartment of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. malifang0606118@126.com.ORCID http://orcid.org/0000-0001-5429-193X
Tianxiang ChenDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. txchen@shsmu.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32470821National Natural Science Foundation of China (National Science Foundation of China) 82272679National Natural Science Foundation of China (National Science Foundation of China) 82273139National Natural Science Foundation of China (National Science Foundation of China) 82303043National Natural Science Foundation of China (National Science Foundation of China) 82472771
6 · The paper itself

Abstract

While third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as osimertinib, have significantly improved patient survival in non-small cell lung cancer (NSCLC), acquired resistance remains a major clinical challenge, and its underlying mechanisms are incompletely understood. In this study, we demonstrate that YTHDC2 expression is significantly downregulated in osimertinib-resistant patient-derived xenograft (PDX) tissues and lung cancer cell lines compared to their osimertinib-sensitive counterparts. Further investigation revealed that YTHDC2 overcomes osimertinib resistance in lung cancer cells by promoting cuproptosis. Mechanistically, YTHDC2 binds to m

Indexed as

Carcinoma, Non-Small-Cell LungCopperCopper Transporter 1Drug Resistance, NeoplasmLung NeoplasmsProtein Kinase InhibitorsRNA-Binding ProteinsAcrylamidesAniline CompoundsAnimalsCell Line, TumorErbB ReceptorsGene Expression Regulation, NeoplasticHumansIndolesMiceAcrylamidesAniline CompoundsCopperCopper Transporter 1EGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesRNA-Binding ProteinsSLC31A1 protein, human

Identifiers

PMID41402633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.